Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19
As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for accelerated development is the evaluation of drug combinations in the absence of prior monotherapy data. This approach is appealing for a number of reasons. First, combining two or more drugs with related or complementary therapeutic effects permits a multipronged approach addressing the variable pathways of the disease. Second, if an individual component of a combination offers a therapeutic effect, then in the absence of antagonism, a trial of combination therapy should still detect individual efficacy. Third, this strategy is time saving. Rather than taking a stepwise approach to evaluating monotherapies, this strategy begins with testing all relevant therapeutic options. Finally, given the severity of the current pandemic and the absence of treatment options, the likelihood of detecting a treatment effect with combination therapy maintains scientific enthusiasm for evaluating repurposed treatments. Antiviral combination selection can be facilitated by insights regarding SARS-CoV-2 pathophysiology and cell cycle dynamics, supported by infectious disease and clinical pharmacology expert advice. We describe a clinical evaluation strategy using adaptive combination platform trials to rapidly test combination therapies to treat COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
The American journal of tropical medicine and hygiene - 103(2020), 4 vom: 22. Okt., Seite 1364-1366 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rayner, Craig R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
145155-23-3 |
|---|
| Anmerkungen: |
Date Completed 27.10.2020 Date Revised 14.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4269/ajtmh.20-0995 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314017755 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314017755 | ||
| 003 | DE-627 | ||
| 005 | 20231225151826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4269/ajtmh.20-0995 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314017755 | ||
| 035 | |a (NLM)32828137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rayner, Craig R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2020 | ||
| 500 | |a Date Revised 14.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for accelerated development is the evaluation of drug combinations in the absence of prior monotherapy data. This approach is appealing for a number of reasons. First, combining two or more drugs with related or complementary therapeutic effects permits a multipronged approach addressing the variable pathways of the disease. Second, if an individual component of a combination offers a therapeutic effect, then in the absence of antagonism, a trial of combination therapy should still detect individual efficacy. Third, this strategy is time saving. Rather than taking a stepwise approach to evaluating monotherapies, this strategy begins with testing all relevant therapeutic options. Finally, given the severity of the current pandemic and the absence of treatment options, the likelihood of detecting a treatment effect with combination therapy maintains scientific enthusiasm for evaluating repurposed treatments. Antiviral combination selection can be facilitated by insights regarding SARS-CoV-2 pathophysiology and cell cycle dynamics, supported by infectious disease and clinical pharmacology expert advice. We describe a clinical evaluation strategy using adaptive combination platform trials to rapidly test combination therapies to treat COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Interferon beta-1b |2 NLM | |
| 650 | 7 | |a 145155-23-3 |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Dron, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jay J H |e verfasserin |4 aut | |
| 700 | 1 | |a Decloedt, Eric H |e verfasserin |4 aut | |
| 700 | 1 | |a Cotton, Mark F |e verfasserin |4 aut | |
| 700 | 1 | |a Niranjan, Vis |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Patrick F |e verfasserin |4 aut | |
| 700 | 1 | |a Dodds, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Fran |e verfasserin |4 aut | |
| 700 | 1 | |a Reis, Gilmar |e verfasserin |4 aut | |
| 700 | 1 | |a Wesche, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Edward J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of tropical medicine and hygiene |d 1945 |g 103(2020), 4 vom: 22. Okt., Seite 1364-1366 |w (DE-627)NLM000012513 |x 1476-1645 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2020 |g number:4 |g day:22 |g month:10 |g pages:1364-1366 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4269/ajtmh.20-0995 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2020 |e 4 |b 22 |c 10 |h 1364-1366 | ||